Indian J Pharm Close
 

Figure 2: Overall survival (OS) of patients receiving 12 weeks of adjuvant or neoadjuvant trastuzumab

Figure 2: Overall survival (OS) of patients receiving 12 weeks of adjuvant or neoadjuvant trastuzumab